Agency Must Discuss Evaluated Weaknesses
Client Alert | less than 1 min read | 09.14.04
In defending its award decision before the GAO in Cygnus Corp., Inc. (Dec. 30, 2003), the National Institutes of Health ("NIH") cited a number of weaknesses in the protester's proposal, but had failed to raise those same weaknesses with the protester during discussions. NIH compounded this error by suggesting in discussions that the protester had adequately resolved a number of other problems also cited by the agency as a basis for the award decision, and the GAO recommended another round of discussions, offers, and a reevaluation.
Contacts
Insights
Client Alert | 3 min read | 03.02.26
Clinical trial sponsors and all other stakeholders involved in conducting commercial clinical trials of investigational medicinal products (IMP) in the UK.
Client Alert | 4 min read | 03.02.26
Client Alert | 3 min read | 02.27.26
Client Alert | 6 min read | 02.27.26

